OncoMed starts Phase Ia of anti-TIGIT antibody to treat solid tumors

OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) began a Phase Ia trial evaluating OMP-313M32 to treat advanced or metastatic solid tumors. The open-label, dose-escalation, U.S. trial will evaluate IV OMP-313M32 every 2 weeks in about 30 patients. The primary endpoint is safety. Secondary endpoints include pharmacokinetics, immunogenicity, objective response rate (ORR) and progression-free survival (PFS)...